Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+, Mozilla Firefox 20+, Internet Explorer 11, Opera 15–18, Apple Safari 7, SeaMonkey 2.15-2.23

TAT 2018 – Targeted Anticancer Therapies

The home of phase 1 oncology

Start date: 05 Mar 2018
End date: 07 Mar 2018
Location: Paris, France

In a constantly evolving oncology environment, ESMO continues to expand its educational offer and conference portfolio and is pleased to announce that as of 2018 ESMO is taking on the TAT Congress, which will now be held on an annual basis in Europe.

Create your own personalised agenda and browse the complete scientific programme by day, topic, cancer type and track with the ESMO events app.

The goals and the design of phase 1 studies have changed from just safety/toxicity to now include clinical activity/response and biomarker research. This new phase 1 paradigm has already led to rapid, conditional, approval of several new cancer therapeutics showing outstanding clinical activity in early-phase studies.

TAT focuses on early-phase development and translational research. The programme covered targeted agents, immuno-oncology and combinations involving such agents.